Related Experiment Videos
Summary
Alpha-1 antitrypsin (AAT) is a protein that reduces inflammation and protects against emphysema. AAT therapy shows promise in preventing autoimmune diseases and graft loss by modulating immune responses.
Area of Science:
- Immunology
- Pulmonology
- Biochemistry
Background:
- Alpha-1 antitrypsin (AAT) is a serpin inhibiting neutrophil elastase, crucial for preventing lung emphysema.
- AAT is an acute-phase protein with anti-inflammatory properties, inhibiting cytokines, apoptosis, and leukocyte activity.
- AAT influences monocyte function by affecting cAMP, CD14 expression, and NFκB signaling, potentially via serpin or other binding activities.
Purpose of the Study:
- To review the immune-modulating effects of Alpha-1 antitrypsin (AAT).
- To explore the therapeutic potential of AAT in autoimmune diseases and transplantation.
Main Methods:
- Literature review of preclinical and clinical studies on AAT's immunomodulatory functions.
- Analysis of AAT's effects on cytokine profiles, transcriptional changes, and T cell subsets in disease models.
Main Results:
- AAT demonstrates broad anti-inflammatory effects, including cytokine suppression and inhibition of leukocyte migration.
- Preclinical studies show AAT therapy can prevent or reverse autoimmune disease and graft rejection.
- Therapeutic administration of AAT induces tolerogenic immune profiles.
Conclusions:
- AAT possesses significant immunomodulatory capabilities beyond its serpin activity.
- AAT therapy holds therapeutic promise for autoimmune conditions and preventing graft loss.
- Further research into AAT's mechanisms and clinical applications is warranted.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
30
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
30
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K